What patients are prescribed instead is flower or oil for vaporisation, and the equipment, the temperature and the cost structure that follow from that decision are considerably more interesting than the debate that usually surrounds the subject.
The reasoning is clinical rather than moral. Burning plant material produces tar, carbon monoxide and a range of combustion by-products with no therapeutic function and well-documented respiratory consequences.
Vaporisation heats material below the point of combustion, releasing the target compounds as vapour without producing the same by-product profile. The distinction is what allowed a plant-based medicine to be prescribable at all within a framework that would never license a product administered by smoking.
It also means the delivery device is part of the treatment rather than an accessory, which most coverage of this subject misses entirely.
Prescriptions are dispensed through pharmacies, and that is a more significant part of the picture than patients often realise.
The General Pharmaceutical Council regulates pharmacies and pharmacy professionals across Great Britain, maintaining registers and setting standards for the people and premises involved. Its role covers the regulation of pharmacy practice, including the professional obligations of the pharmacist who dispenses an unlicensed medicine.
That matters because most cannabis-based medicinal products are unlicensed specials, which places specific responsibilities on the dispensing pharmacy around sourcing, record-keeping and counselling the patient. Dispensing pharmacists are expected to provide appropriate counselling on the safe use of prescribed medicines, including how they should be administered.
This is where the sector becomes genuinely difficult to assess from outside, because pricing is opaque and varies widely.
The costs a patient faces divide into four: the initial consultation, follow-up appointments, the medicine itself, and the device. Only the last is a one-off. The medicine is the dominant recurring cost and it scales with dose, which means a patient on a higher dose faces a materially different monthly figure from one on a low dose of the same product.
Devices range from budget conduction units to convection devices costing several hundred pounds, and unlike the medicine they are not prescribed, so the patient buys them separately.
Comparing providers on headline consultation fees alone is therefore close to meaningless. Directories comparing the best cannabis clinic can provide a useful starting point, but the number that matters is the full annual cost including medicine, and that figure is rarely displayed prominently.
Different compounds in cannabis volatilise at different temperatures, which is why the setting on the device produces materially different results from the same material.
Lower settings tend to release the more volatile compounds, including many of the aromatic terpenes, and produce a lighter vapour. Higher settings release more of the cannabinoid content and produce a denser vapour, at the cost of degrading some of the lighter compounds and, at the top of the range, approaching combustion.
There is no single correct figure, which is precisely why patients ask about it constantly. Explanations addressing what temperature does cannabis vaporize? set out the ranges involved and why the answer depends on the product and the intended effect. Patients should follow the instructions provided by their prescriber, as the method of administration forms part of the prescribed treatment plan.
Devices divide into two heating approaches and the difference is functional rather than marketing.
Conduction devices heat material by direct contact with a hot surface. They are cheaper, simpler and heat faster, but they can produce less even heating, with material closest to the element reaching higher temperatures than the rest.
Convection devices pass heated air through the material. They deliver more consistent extraction and better temperature control, and they generally cost significantly more.
For occasional use the difference may be relatively small. For a patient using a device several times daily over an extended period, consistency of dose may become a more important consideration.
Two structural features explain most of the pricing behaviour.
Almost all of these products are unlicensed imports, which means supply chains are longer, smaller in volume and more exposed to currency and logistics costs than licensed medicines. And because NHS prescribing remains relatively limited, there is no large public purchaser exerting downward pressure on price.
The result is a market where a medicine that is legal, regulated and clinically prescribed may still require patients to meet the full commercial cost of treatment. For many people, that ongoing cost is one of the most significant practical considerations when exploring medical cannabis treatment.
Patients may find it helpful to ask a few practical questions before starting treatment:
Having clear answers to these questions can help patients better understand both the practical and financial aspects of treatment.
Disclaimer: This article is provided for general information only and should not be regarded as medical advice. Medical cannabis is a prescription-only medicine in the UK and is not suitable for everyone. Decisions about treatment, dosage, method of administration and device selection should always be made in consultation with an appropriately qualified healthcare professional. References to clinics or information resources are provided for informational purposes only and do not constitute an endorsement or recommendation of any particular provider.
